4-((甲基磺酰基)甲基)苯甲醛 | 156867-56-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-((甲基磺酰基)甲基)苯甲醛
• 英文名称: 4-(methylsulfonylmethyl)benzaldehyde
• 英文别名: 4-[(methylsulfonyl)methyl]benzaldehyde；4-((Methylsulfonyl)methyl)benzaldehyde
• CAS: 156867-56-0
• 化学式: C₉H₁₀O₃S
• 分子量: 198.243
• InChiKey: RUZRGRDECVOHGI-UHFFFAOYSA-N

物化性质

• 沸点：
  432.5±28.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件为2-8°C，并需保存在惰性气体中。

反应信息

• 作为反应物：
  描述：

  4-((甲基磺酰基)甲基)苯甲醛 、 丙二酸二乙酯 在 5%-palladium/activated carbon 、 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 20.0~50.0 ℃ 、101.33 kPa 条件下， 反应 66.0h， 生成 diethyl 2-[[4-(methylsulfonylmethyl)phenyl]methyl]propanedioate
  参考文献：
  名称：

  Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation

  摘要：

  Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate, utilizing NADH as a cofactor. It has been identified as a potential therapeutic target in the area of cancer metabolism. In this manuscript we report our progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors. Fragment hits were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking. Also reported is their modification into cellular active compounds suitable for target validation work.

  DOI：

  10.1021/jm201734r
• 作为产物：
  描述：

  4-溴甲基苯甲醛 、 methanesulfonic acid sodium salt 以 乙醇 为溶剂， 反应 2.0h， 以85%的产率得到4-((甲基磺酰基)甲基)苯甲醛
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE SOUS FORME DE PYRAZOLOPYRIMIDINES

  摘要：

  本发明一般涉及激酶的抑制剂，更具体地涉及新型吡唑吡嘧啶化合物。

  公开号：

  WO2004009602A1

文献信息

• PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS
  申请人：SmithKline Beecham Corporation

  公开号：EP1551841A1

  公开（公告）日：2005-07-13
• [EN] PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE SOUS FORME DE PYRAZOLOPYRIMIDINES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004009602A1

  公开（公告）日：2004-01-29

  The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.

  本发明一般涉及激酶的抑制剂，更具体地涉及新型吡唑吡嘧啶化合物。
• Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation
  作者：Richard A. Ward、Claire Brassington、Alexander L. Breeze、Alessandro Caputo、Susan Critchlow、Gareth Davies、Louise Goodwin、Giles Hassall、Ryan Greenwood、Geoffrey A. Holdgate、Michael Mrosek、Richard A. Norman、Stuart Pearson、Jonathan Tart、Julie A. Tucker、Martin Vogtherr、David Whittaker、Jonathan Wingfield、Jon Winter、Kevin Hudson

  DOI：10.1021/jm201734r

  日期：2012.4.12

  Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate, utilizing NADH as a cofactor. It has been identified as a potential therapeutic target in the area of cancer metabolism. In this manuscript we report our progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors. Fragment hits were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking. Also reported is their modification into cellular active compounds suitable for target validation work.